Rheumatology Advance Access published online on June 30, 2009
Rheumatology, doi:10.1093/rheumatology/kep163
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Comment on: Possible miliary tuberculosis during adalimumab therapy with negative
-IFN release assays
1Kennedy Institute of Rheumatology Division, Imperial College London and 2Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK
Correspondence to:
Pamela Mangat, Kennedy Institute of Rheumatology Division, Imperial College London, 65 Aspenlea Road, Hammersmith, Greater London W6 8LH, UK. E-mail: Pamela.mangat@imperial.ac.uk
| The first 10% of the full text of this article appears below. |
SIR, We read with interest the case of Possible miliary tuberculosis during adalimumab therapy with negative
-IFN release assays published by Endean et al. [1]. We suggest that the negative QuantiFERON-TB
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. L. Endean, S. M. Barry, and S. A. Young-Min Comment on: Possible miliary tuberculosis during adalimumab therapy with negative {gamma}-IFN release assays: reply Rheumatology, September 1, 2009; 48(9): 1178 - 1178. [Full Text] [PDF] |
||||
